PharmAust (ASX:PAA) has announced that the Trial Safety Committee has approved an escalation of the Monepantel (MPL) dose in a trial in patients with Motor Neurone Disease (MND).
The committee evaluated the trial for adverse events and pharmacokinetic information of MPL absorption. It confirmed there were no reported safety issues. The pharmacokinetic data also confirmed drug absorption.
PharmAust said it would continue to supply MPL tablets to all six patients in cohort one that elected to remain on the treatment. The trial is open-label and comprises a four-week escalating dose of MPL.
Patient recruitment at the next MPL dosing level has commenced with four new patients undergoing screening, said the company.
This Phase1/2 trial is being funded by $881,085 from FightMND, the largest independent MND research funder in Australia.